[{"id":"4e42d859-13fd-4f02-9114-fb8f31fc6d67","acronym":"PALBREAST","url":"https://clinicaltrials.gov/study/NCT06403904","created_at":"2024-05-08T20:30:18.642Z","updated_at":"2024-07-02T16:35:05.050Z","phase":"","brief_title":"Assessing Clinical Features and Outcome of Breast Cancer in PALB2 Mutation Carriers: the Palbreast Study","source_id_and_acronym":"NCT06403904 - PALBREAST","lead_sponsor":"Azienda Ospedaliero-Universitaria di Modena","biomarkers":" PALB2 • BRCA","pipe":"","alterations":" ","tags":["PALB2 • BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-08"},{"id":"10d0956a-4ec0-46e8-936a-8b03707ecfe5","acronym":"NEO","url":"https://clinicaltrials.gov/study/NCT02489006","created_at":"2021-01-18T11:59:49.235Z","updated_at":"2025-02-25T15:06:39.652Z","phase":"Phase 2","brief_title":"A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","source_id_and_acronym":"NCT02489006 - NEO","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 07/19/2016","start_date":" 07/19/2016","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-17"},{"id":"ed563a44-6690-43de-8e0f-3b02cbfba381","acronym":"GURC","url":"https://clinicaltrials.gov/study/NCT03501173","created_at":"2021-01-18T17:14:34.330Z","updated_at":"2024-07-02T16:35:42.123Z","phase":"","brief_title":"A Study of Participants With Advanced Prostate Cancer in Canada","source_id_and_acronym":"NCT03501173 - GURC","lead_sponsor":"Janssen Inc.","biomarkers":" BRCA1 • BRCA2 • AR • HRD • PALB2","pipe":" | ","alterations":" ATM mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • AR • HRD • PALB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 374","initiation":"Initiation: 04/12/2018","start_date":" 04/12/2018","primary_txt":" Primary completion: 07/14/2023","primary_completion_date":" 07/14/2023","study_txt":" Completion: 07/14/2023","study_completion_date":" 07/14/2023","last_update_posted":"2023-07-25"},{"id":"d02391ff-25e8-4dc6-a678-f59e43b84773","acronym":"","url":"https://clinicaltrials.gov/study/NCT02478892","created_at":"2021-01-18T11:56:17.028Z","updated_at":"2024-07-02T16:35:42.564Z","phase":"","brief_title":"Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk","source_id_and_acronym":"NCT02478892","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" BRCA1 • BRCA2 • ATM • PALB2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • ATM • PALB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-07-19"},{"id":"c32a9424-3409-40c6-a992-e2f21929c6bf","acronym":"RADIOLA","url":"https://clinicaltrials.gov/study/NCT05340413","created_at":"2022-04-22T14:53:48.015Z","updated_at":"2024-07-02T16:35:50.312Z","phase":"Phase 2","brief_title":"Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.","source_id_and_acronym":"NCT05340413 - RADIOLA","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • HRD • PALB2 • RAD51 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51C mutation • RAD51D mutation • PGR negative • RAD51 mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • HRD • PALB2 • RAD51 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51C mutation • RAD51D mutation • PGR negative • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-04-18"},{"id":"1613ce9f-62e8-40ce-ad27-ff6fc94df26f","acronym":"Lung-Map Sub-Study","url":"https://clinicaltrials.gov/study/NCT03377556","created_at":"2021-01-18T16:40:11.324Z","updated_at":"2024-07-02T16:36:28.736Z","phase":"Phase 2","brief_title":"Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer","source_id_and_acronym":"NCT03377556 - Lung-Map Sub-Study","lead_sponsor":"Southwest Oncology Group","biomarkers":" BRCA1 • BRCA2 • HRD • PALB2 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCM • FANCD2 • RPA1 • FANCC","pipe":" | ","alterations":" BARD1 mutation • RPA1 mutation","tags":["BRCA1 • BRCA2 • HRD • PALB2 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCM • FANCD2 • RPA1 • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BARD1 mutation • RPA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 01/10/2021","primary_completion_date":" 01/10/2021","study_txt":" Completion: 04/16/2021","study_completion_date":" 04/16/2021","last_update_posted":"2021-06-23"},{"id":"11e16434-34d8-4653-a1d6-b7f7efe9e5db","acronym":"","url":"https://clinicaltrials.gov/study/NCT03419247","created_at":"2021-01-18T16:52:10.466Z","updated_at":"2024-07-02T16:36:32.584Z","phase":"","brief_title":"Molecular Profiling of Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT03419247","lead_sponsor":"University Health Network, Toronto","biomarkers":" ATM • PALB2 • BRCA","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • BRCA mutation","tags":["ATM • PALB2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • BRCA mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/02/2022","primary_completion_date":" 01/02/2022","study_txt":" Completion: 01/02/2023","study_completion_date":" 01/02/2023","last_update_posted":"2021-04-01"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"b6e48fdd-5bcf-46b3-969d-42178823f3fb","acronym":"PROREPAIR-B","url":"https://clinicaltrials.gov/study/NCT03075735","created_at":"2021-01-17T17:57:03.264Z","updated_at":"2024-07-02T16:37:03.220Z","phase":"","brief_title":"Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)","source_id_and_acronym":"NCT03075735 - PROREPAIR-B","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" BRCA1 • BRCA2 • PALB2","pipe":" | ","alterations":" PALB2 mutation","tags":["BRCA1 • BRCA2 • PALB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 408","initiation":"Initiation: 01/15/2013","start_date":" 01/15/2013","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 12/15/2018","study_completion_date":" 12/15/2018","last_update_posted":"2019-02-04"}]